(1) Sarcopenia is a progressive loss of skeletal muscle mass and strength. The aim of this study was to determine the association of sarcopenia, defined according to the Working Group on Sarcopenia in Older People (EWGSOP2) diagnostic criteria, with mortality at 24 months in very elderly hemodialysis patients. (2) A prospective study was conducted in 60 patients on chronic hemodialysis who were older than 75 years. Sarcopenia was diagnosed according to EWGSOP2 criteria. Additionally, clinical, anthropometric and analytical variables and body composition by bioimpedance were assessed. The date and cause of death were recorded during 2 years of follow-up. (3) Among study participants, 41 (68%) were men, the mean age 81.85 ± 5.58 years and the dialysis vintage was 49.88 ± 40.29 months. The prevalence of probable sarcopenia was 75% to 97%, depending on the criteria employed: confirmed sarcopenia ranged from 37 to 40%, and severe sarcopenia ranged from 18 to 37%. A total of 30 (50%) patients died over 24 months. Sarcopenia probability variables were not related to mortality. In contrast, sarcopenia confirmation (appendicular skeletal muscle mass, ASM) and severity (gait speed, GS) variables were associated with mortality. In multivariate analysis, the hazard ratio (95% confidence interval) for all-cause death was 3.03 (1.14–8.08, p = 0.028) for patients fulfilling ASM sarcopenia criteria and 3.29 (1.04–10.39, p = 0.042) for patients fulfilling GS sarcopenia criteria. (4) The diagnosis of sarcopenia by EWGSOP2 criteria is associated with an increased risk of all-cause death in elderly dialysis patients. Specifically, ASM and GS criteria could be used as mortality risk markers in elderly hemodialysis patients. Future studies should address whether the early diagnosis and treatment of sarcopenia improve outcomes.

Background In 2019, EWGSOP2 proposed 4 steps to diagnose and assess sarcopenia. We aimed to quantify the prevalence of sarcopenia according to the EWGSOP2 diagnostic algorithm and to assess its applicability in elderly patients on hemodialysis. Methods Prospective study of 60 outpatients on chronic hemodialysis aged 75- to 95-years, sarcopenia was assessed according to the 4-step EWGSOP2: Find: Strength, Assistance walking, Rise from a chair, Climb stairs, and Falls (SARC-F); Assess: grip strength by dynamometry (GSD) and sit to stand to sit 5 (STS5); Confirm: appendicular skeletal muscle mass (ASM) by bioimpedance; Severity: gait speed (GS), Timed-Up and Go (TUG), and Short Physical Performance Battery (SPPB). Results The sequential four steps resulted in a prevalence of confirmed or severe sarcopenia of 20%. Most (97%) patients fulfilled at least one criterion for probable sarcopenia. The sensitivity of SARC-F for confirmed sarcopenia was low (46%). Skipping the SARC-F step increased the prevalence of confirmed and severe sarcopenia to 40% and 37%, respectively. However, 78% of all patients had evidence of dynapenia consistent with severe sarcopenia. Muscle mass (ASM) was normal in 60% of patients, while only 25% had normal muscle strength values (GSD). Conclusions According to the 4-step EWGSOP2, the prevalence of confirmed or severe sarcopenia was low in elderly hemodialysis patients. The diagnosis of confirmed sarcopenia underestimated the prevalence of dynapenia consistent with severe sarcopenia. Future studies should address whether a 2-step EWGSOP2 assessment (Assess-Severity) is simpler to apply and may provide better prognostic information than 4-step EWGSOP2 in elderly persons on hemodialysis.

Sarcopenia is a highly prevalent condition in persons on hemodialysis. In stable very elderly (75- to 95-year-old) persons on chronic hemodialysis, we prospectively studied the European Working Group on Sarcopenia in Older People (EWGSOP2) steps stability over time in 37 controls and their response to a 12-week intradialytic lower limb exercise program in 23 persons. Overall dropout was 15% and the main cause for dropout was death (8%). Thus, 33 controls and 18 exercise participants were evaluated at 12 weeks. In controls, comorbidity, nutrition, dependency and frailty scales, anthropometric assessments, EWGSOP2 step values and the prevalence of suspected, confirmed, and severe sarcopenia as assessed by EWGSOP2 remained stable. By contrast, in persons that completed the exercise program a significant improvement in the sit-to-stand-5 test was noted at the end of the 12-week exercise program (19.2 ± 4.9 to 15.9 ± 5.9 seconds, p = 0.001), consistent with the lower limb nature of the exercise program, that persisted 12 weeks after completion of the program. Exercise also improved the FRIED frailty scale (1.7 ± 1.0 to 1.1 ± 0.6,  p = 0.004). In conclusion, EWGSOP2 steps remain stable in stable very elderly persons in hemodialysis and sit-to-stand-5 is responsive to a short-term intradialytic lower limb exercise program. These results may help define EWGSOP2-based primary endpoints in future large scale clinical trials assessing exercise interventions.

Objetivo: Analizar el impacto de la variabilidad intramétodo de la Termodilución (TD) en las medidas prospectivas de flujo de acceso (QA) y su relación con los parámetros de seguimiento de primera generación. Método: Estudio prospectivo. Se realizaron 2 mediciones consecutivas de QA (M1 y M2) y un seguimiento (M3) en 6 meses. Se recogieron datos demográficos y parámetros de seguimiento de primera generación. Resultado: Se analizaron 112 fistulas arteriovenosas(FAV). La mediana de la variabilidad generada entre M1 y M2 no difiere del porcentaje de variación de QA a los 6 meses (p=0,123). En el 16,8% (14) de los pacientes el QA ha disminuido más del 25% y en un 28,9% (24) aumentó más del 25%. Se evidenció una ligera tendencia a aumentar el porcentaje de descenso de QA a medida que el flujo de las fístulas es mayor (r=-0,229; p=0,006). Por otra parte, un descenso de QA superior al 25% no se asoció a menor dosis de diálisis (p=0,183), ni ha aumento significativo de la presión venosa dinámica (p=0,823) ni al aumento de incidencias durante la punción (p=0,823). Conclusiones: La presencia de pacientes con aumento de flujo superior a la variabilidad intramétodo y la no asociación entre un descenso superior al 25% y cambios en otros parámetros de seguimiento, hace sospechar la presencia de errores de medición de QA. Frente a ello es conveniente el uso combinado con métodos de primera generación, tanto para establecer el QA basal como para interpretar los descensos en el seguimiento.

(1) Background: Persons with chronic kidney disease may have sarcopenia characterized by the loss of muscle mass and loss of muscle strength. However, EWGSOP2 criteria to diagnose sarcopenia are technically challenging, especially in elderly persons on hemodialysis. Sarcopenia may be associated with malnutrition. We aimed at defining a sarcopenia index derived from malnutrition parameters for use in elderly haemodialysis patients. (2) Methods: A retrospective study of 60 patients aged 75 to 95 years treated with chronic hemodialysis was conducted. Anthropometric and analytical variables, EWGSOP2 sarcopenia criteria and other nutrition-related variables were collected. Binomial logistic regressions were used to define the combination of anthropometric and nutritional parameters that best predict moderate or severe sarcopenia according to EWGSOP2, and performance for moderate and severe sarcopenia was assessed by the area under the curve (AUC) of receiver operating characteristic (ROC) curves. (3) Results: The combination of loss of strength, loss of muscle mass and low physical performance correlated with malnutrition. We developed regression-equation-related nutrition criteria that predicted moderate sarcopenia (elderly hemodialysis sarcopenia index-moderate, EHSI-M) and severe sarcopenia (EHSI-S) diagnosed according to EWGSOP2 with an AUC of 0.80 and 0.866, respectively. (4) Conclusions: There is a close relationship between nutrition and sarcopenia. The EHSI may identify EWGSOP2-diagnosed sarcopenia from easily accessible anthropometric and nutritional parameters.